Takara Bio's cost-cutting program is running hotter than planned, and its exit from contract cell manufacturing now has named counterparties attached. Takara Holdings, parent of the delisted biotech unit, told Tokyo's exchange on July 21 that a voluntary retirement scheme drew 148 applicants against a target of "around 120," pushing the one-off charge for the year to March 2027 to ¥1.71bn, above the ¥1.44bn originally budgeted.
Employees applied between June 15 and July 17, with departures set for October 31. Retirees get standard severance plus a top-up payment and job-placement support. Of the ¥1.71bn charge, ¥1.65bn will land in the first quarter's results as an extraordinary loss. The larger headcount cut also lifts the payoff: Takara Bio now expects ¥1.11bn in annual personnel-cost savings, up from an initial ¥720mn estimate, with ¥576mn of that landing in the year to March 2027 against an original ¥300mn plan. The company says the revised figures were already folded into the outlook it published on May 13, so the net effect on guidance is minor.
| Metric | Initial Plan | Updated Figure |
|---|---|---|
| Extraordinary loss, year to March 2027 | ¥1.44bn | ¥1.71bn |
| Annual personnel-cost savings | ¥720mn | ¥1.11bn |
| Personnel savings, year to March 2027 | ¥300mn | ¥576mn |
The other half of the announcement is who takes over the business Takara Bio is leaving. The company signed a basic agreement on July 21 with Sumitomo Chemical, Sumitomo Pharma, and their joint venture S-RACMO to transfer its GMP cell-processing contract manufacturing operation. The four parties still have to negotiate which staff, assets, and client contracts move, plus how the businesses cooperate after the handoff. Takara Bio wants a final contract by around October 2026, and executing the transfer depends on meeting conditions written into that agreement, so nothing is locked in yet. Once the deal closes, Takara Bio plans to concentrate its remaining contract-manufacturing work on nucleic acids and plasmids, proteins and enzymes, and viral vectors.
A related but separate question, the fate of TBI-1301, Takara Bio's in-house gene therapy candidate, is still being negotiated with the Sumitomo Chemical group, with no terms disclosed.
On governance, the company has already carried out the accountability steps it flagged in May. The board shrank from nine directors to three, a change approved at the 24th annual shareholders meeting. The chairman and president voluntarily returned 30% of monthly pay and the vice president 25% between April and June. From July 2026 through June 2027, the president's pay is cut 35%, the vice president's 30%, senior managing executive officers 30%, managing executive officers 25%, and executive officers 20%; one non-executive director is forgoing full pay for the same year.
Two threads remain loose. Takara Bio is still preparing to close its Sweden site but has nothing to disclose yet, and the cost savings from its June 12 delisting are tracking to the original plan without new detail. For a company that delisted five weeks before this update, the message is that restructuring has moved into execution, even though the biggest piece, the Sumitomo Chemical handoff, still rests on a signed final contract rather than money changing hands.